INIS
cancer
100%
breasts
100%
patients
92%
metastases
62%
netherlands
58%
receptors
41%
hormones
38%
carcinomas
25%
therapy
20%
implementation
17%
chemotherapy
16%
decision making
11%
hospitals
11%
biopsy
11%
humans
11%
growth factors
11%
cost
8%
quality of life
8%
tumors
8%
lymph nodes
8%
cost effectiveness analysis
8%
tumor cells
8%
evaluation
8%
comparative evaluations
8%
diseases
7%
utilities
6%
data
5%
hazards
5%
Keyphrases
Netherlands
59%
Breast Cancer
52%
Metastatic Breast Cancer
43%
Advanced Breast Cancer
25%
Estrogen Receptor-positive Metastatic Breast Cancer
25%
Invasive Ductal Carcinoma
22%
Hormone Receptor-positive
18%
Histological Subtypes
18%
Human Epidermal Growth Factor Receptor 2 (HER2)
17%
Invasive Lobular Carcinoma
16%
Cancer Registry
16%
Bevacizumab
16%
HER2-negative Metastatic Breast Cancer
16%
Chemotherapy
15%
Endocrine Therapy
14%
Palliative Chemotherapy
12%
Confidence Interval
12%
Taxanes
11%
Hormone Receptor
11%
Treatment Choice
11%
Everyday Practices
10%
Palliative Systemic Therapy
9%
Breast Cancer Patients
9%
Progression-free Survival
9%
Hospital Type
8%
Everolimus
8%
Exemestane
8%
Outcome-based
8%
Isolated Tumor Cells
8%
Ductal Breast Carcinoma
8%
Medicine and Dentistry
Breast Cancer
62%
Metastatic Breast Cancer
50%
Hormone Receptor
38%
Lobular Carcinoma
25%
Breast Carcinoma
22%
Systemic Therapy
13%
Hormone Therapy
11%
Symptomatic Treatment
9%
Quality of Life
9%
Sentinel Lymph Node Biopsy
8%
Evaluation Study
8%
Tumor Cell
8%
Multiple Myeloma
8%
Decision Making
8%
Cancer Registry
8%
Patient-Reported Outcome
8%
Cost-Effectiveness Analysis
8%
Bevacizumab
8%
Epidermal Growth Factor Receptor 2
8%
Gamma Urogastrone
8%
Diseases
8%
Health Care Cost
7%
Neoplasm
7%
Biopsy Technique
7%
Quality Adjusted Life Year
6%
Comorbidity
5%
